CA
NZ
UK
AU
IND
US
This upward revision comes on the heels of a strong second quarter, where the company saw net sales reach $872.3 million, a notable 13.8% year-over-year increase. The strong performance signals ongoing demand for its products, particularly in the biologics sector, which is driving organic …
Quest Diagnostics delivered an earnings beat that stemmed from a surge in consumer‑focused lab testing, following the announcement of strategic deals with Hims and Oura. The company’s consumer division accounted for a notable portion of its revenue, prompting a sharp rebound in the stock …
This surge marks a notable achievement for investors, who have seen a substantial return on investment. The strong performance has driven the company's market capitalization to approximately $1.2 billion, solidifying its position within the healthcare sector. Investors are keenly aware of market dynamics, and …
The FDA's forthcoming decision regarding the legality of seven peptides, including BPC-157 and TB-500, could significantly influence the availability of these substances in the U.S. market. Current regulatory ambiguities have limited the accessibility of these peptides, which are often discussed in the context of …
Incannex Healthcare Inc. (NASDAQ: IXHL) has officially commenced participant screening for its DReAMzz Phase 2 dose confirmation study of IHL-42X, aimed at treating obstructive sleep apnea. This regulatory advance represents a important point for the company, which has experienced a significant 73.3% decline in …
The increasing popularity of GLP-1 medications, designed primarily for weight loss, is expected to drive a notable uptick in demand for Botox treatments, according to a Swiss aesthetics company. Patients using these medications often face the side effect of facial volume loss, commonly referred …
Inhibikase Therapeutics (NASDAQ: IKT) has achieved a key milestone with the U.S. Food and Drug Administration’s (FDA) decision to grant orphan drug designation for its leading candidate, IKT-001, aimed at treating pulmonary arterial hypertension (PAH). This designation is vital, considering the significant unmet medical …
Phreesia Inc's recent filing of Form DEF 14A has piqued interest among investors regarding its corporate governance practices. This critical document sheds light on upcoming proposals that could serve to enhance the company's operational transparency and accountability. As Phreesia navigates a highly competitive healthcare …
Medpace Holdings, a significant entity in the contract research organization (CRO) sector, has experienced a notable rebound in its financial performance, with its stock rising sharply as a result. The company reported strong bookings that exceeded market expectations, indicating a solid recovery from earlier …
This action signals strong belief in the company's potential, particularly as it prepares to embark on a key Phase 3 clinical trial. Scheduled for the second half of 2026, the trial will involve approximately 111 patients and aims to evaluate the efficacy of urcosimod, …
Please wait processing your request...